Aclaris Therapeutics (ACRS) –
-
Form 8-K Aclaris Therapeutics, For: Mar 14
-
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Walker Neal
-
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Monahan Joseph
-
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin
-
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Powell Andrew Kenneth William
-
Form 10-K Aclaris Therapeutics, For: Dec 31
-
Form 8-K Aclaris Therapeutics, For: Feb 27
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Form SC 13G/A Aclaris Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P.
-
Form SC 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Aclaris Therapeutics, Filed by: CITADEL ADVISORS LLC
-
Form SC 13G Aclaris Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A Aclaris Therapeutics, Filed by: Rock Springs Capital Management LP
-
Form SC 13G/A Aclaris Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P
-
Form SC 13G Aclaris Therapeutics, Filed by: VANGUARD GROUP INC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: Foresite Capital Fund IV, L.P.
-
Form SC 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
-
Form 3 Aclaris Therapeutics, For: Feb 07 Filed by: Leonard Braden Michael
-
Form 4 Aclaris Therapeutics, For: Feb 01 Filed by: Walker Neal
-
Form 4 Aclaris Therapeutics, For: Feb 01 Filed by: Monahan Joseph
-
Form 4 Aclaris Therapeutics, For: Feb 01 Filed by: Loerop James
-
Form 4 Aclaris Therapeutics, For: Feb 01 Filed by: Balthaser Kevin
-
Aclaris Therapeutics (ACRS) Terminates Chief Medical Officer
-
Form 8-K/A Aclaris Therapeutics, For: Jan 15
-
Form 8-K Aclaris Therapeutics, For: Jan 31
-
Form SC 13G/A Aclaris Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: BlackRock Inc.
-
H.C. Wainwright Downgrades Aclaris Therapeutis (ACRS) to Neutral
-
Aclaris Therapeutics (ACRS) Announces CEO Resignation
-
Form 8-K Aclaris Therapeutics, For: Jan 15
-
Form SC 13G Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
-
Aclaris Therapeutics (ACRS) Announces Leadership Changes and Strategic Business Review
-
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
-
BTIG Downgrades Aclaris Therapeutis (ACRS) to Neutral
-
Jefferies Downgrades Aclaris Therapeutis (ACRS) to Hold
-
Aclaris Therapeutics (ACRS) Reports Top-line Results from 4-Week Phase 2b Trial of ATI-1777
-
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
-
Form 4 Aclaris Therapeutics, For: Jan 01 Filed by: Balthaser Kevin
-
Form 4 Aclaris Therapeutics, For: Jan 01 Filed by: Manion Douglas J.
-
Form 8-K Aclaris Therapeutics, For: Dec 19
-
Aclaris Therapeutics (ACRS) Issues Corporate Update
-
Aclaris Therapeutics Provides Corporate Update
-
Aclaris Therapeutis (ACRS) PT Lowered to $1 at Stifel
-
Aclaris Therapeutis (ACRS) PT Raised to $1.50 at Jefferies
-
Form SC 13G Aclaris Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
-
Aclaris Therapeutics (ACRS) Announces Patent License Agreement with Sun Pharma for Alopecia
-
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
-
Form SC 13G Aclaris Therapeutics, Filed by: TANG CAPITAL PARTNERS LP
Back to ACRS Stock Lookup